In the last four years, Grand Pharmaceutical Group's Price has decreased from HK$7.80 to HK$0.00 – a 100.00% drop. In the next year, analysts believe that Fair Value will reach HK$0.00 – an increase of 100.00%. For the next six years, the forecast is forFair Value to grow by 100.00%.

2025 Fair Value Forecast

HK$0.00

2026 Fair Value Forecast

HK$0.00

2027 Fair Value Forecast

HK$0.00

2028 Fair Value Forecast

HK$0.00

2029 Fair Value Forecast

HK$0.00

2030 Fair Value Forecast

HK$0.00

Grand Pharmaceutical Group Revenue Forecast for 2023 - 2025 - 2030

Grand Pharmaceutical Group's Revenue has seen growth In the last two years, going from HK$6.35B to HK$9.56B – a gain of 50.52% For the following year, the 0 analysts predict that Grand Pharmaceutical Group's Revenue will drop by 15.42%, reaching HK$8.09B. In 2030, the professionals' prediction is that 512's Revenue will decrease by 14.10%, reaching HK$8.21B.

2023 Rev Forecast

HK$8.09B

2024 Rev Forecast

HK$7.60B

2025 Rev Forecast

HK$7.97B

2026 Rev Forecast

HK$8.50B

2027 Rev Forecast

HK$8.37B

2028 Rev Forecast

HK$8.11B

2029 Rev Forecast

HK$8.07B

2030 Rev Forecast

HK$8.21B

Grand Pharmaceutical Group Dividend per Share Forecast for 2023 - 2025 - 2030

In the last two years, Dividend per Share for Grand Pharmaceutical Group has grown by 27.27%, going from HK$0.11 to HK$0.14. In the following year, the 0 analysts surveyed believe that Grand Pharmaceutical Group's Dividend per Share will decrease by 14.29%, reaching HK$0.12. According to professionals, by 2030, Grand Pharmaceutical Group's Dividend per Share will have decreased by 13.29%, falling down to HK$0.12.

2023 DPS Forecast

HK$0.12

2024 DPS Forecast

HK$0.12

2025 DPS Forecast

HK$0.12

2026 DPS Forecast

HK$0.12

2027 DPS Forecast

HK$0.12

2028 DPS Forecast

HK$0.12

2029 DPS Forecast

HK$0.12

2030 DPS Forecast

HK$0.12

Grand Pharmaceutical Group Free Cash Flow Forecast for 2023 - 2025 - 2030

Grand Pharmaceutical Group EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, Grand Pharmaceutical Group's EBITDA has increased by 60.53%, going from HK$2.07B to HK$3.33B. According to the 0 analysts polled, in the next year, Grand Pharmaceutical Group's EBITDA will fall by 22.24%, reaching HK$2.59B. By 2030, professionals believe that Grand Pharmaceutical Group's EBITDA will have decreased by 19.58%, falling to HK$2.68B.

2023 EBITDA Forecast

HK$2.59B

2024 EBITDA Forecast

HK$2.47B

2025 EBITDA Forecast

HK$2.54B

2026 EBITDA Forecast

HK$2.80B

2027 EBITDA Forecast

HK$2.73B

2028 EBITDA Forecast

HK$2.65B

2029 EBITDA Forecast

HK$2.62B

2030 EBITDA Forecast

HK$2.68B

Grand Pharmaceutical Group EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Grand Pharmaceutical Group's EBIT has grown, increasing from HK$1.80B to HK$2.97B – an increase of 64.68%. For the next year, 0 analysts project Grand Pharmaceutical Group's EBIT to drop by 23.45%, reaching HK$2.27B. By 2030, professionals believe that Grand Pharmaceutical Group's EBIT will decrease by 20.49%, reaching HK$2.36B – a concerning trend for the company.

2023 EBIT Forecast

HK$2.27B

2024 EBIT Forecast

HK$2.17B

2025 EBIT Forecast

HK$2.23B

2026 EBIT Forecast

HK$2.48B

2027 EBIT Forecast

HK$2.41B

2028 EBIT Forecast

HK$2.33B

2029 EBIT Forecast

HK$2.30B

2030 EBIT Forecast

HK$2.36B

Grand Pharmaceutical Group EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last four years, Grand Pharmaceutical Group's EPS has decreased from HK$0.52 to HK$0.00 – a 100.00% drop. In the next year, analysts believe that EPS will reach HK$0.00 – an increase of 100.00%. For the next six years, the forecast is forEPS to grow by 100.00%.

2025 EPS Forecast

HK$0.00

2026 EPS Forecast

HK$0.00

2027 EPS Forecast

HK$0.00

2028 EPS Forecast

HK$0.00

2029 EPS Forecast

HK$0.00

2030 EPS Forecast

HK$0.00